Philosophy of Care
Dr. Rolder admires the courage and fortitude that her cancer patients show on a daily basis and tries to help them through this difficult period. She researches all available treatment options and advise each patient as she would a family member. Her goal is to provide my patients with clear information in understandable language, and then to partner with them to decide which is the best treatment for them. She is a strong advocate for her patients and promise to support them during each stage of their cancer care.
Dr. Rodler is a clinician investigator in both breast cancer and sarcoma.
Dr. Rodler’s research interests are in triple negative breast cancer treatment. She specializes in breast cancer clinical care and research. Her area of research interest in is hormone receptor negative, HER2/neu negative breast cancer ("Triple negative breast cancer").
She is the principal investigator for a phase I clinical trial in patients with metastatic triple negative breast cancer which is exploring the efficacy of using a chemotherapy drug combination that causes DNA damage, and a new drug called a “PARP inhibitor” which acts as a double hit to these tumor cells. Poly (ADP-ribose) polymerase (PARP) inhibitors inhibit DNA repair in cancer cells that have pre-existing DNA repair defects, but not normal cells.
4501 X Street, 2nd Floor
Sacramento, CA 95817
Physician Referrals: 800-4-UCDAVIS (800-482-3284)
M.A., Yale University, New Haven, CT, 1983
B.A., Stanford University, Stanford, CA, 1981
American Board of Medical Oncology,
Physicians for a National Health Program
Southwest Oncology Group
Select Recent Publications:
Burt A, Berriochoa J, Korpak A, Rodler E, Jones RL, Weisstein J, Patel S. Treatment of Chest Wall Sarcomas: A Single-Institution Experience Over 20 years. Am J Clinic Oncol 2013. April 3. Published online ahead of print.
Schroeder BA, Rodler ET, Loggers ET, Pollack SM. Clinical benefit of trabectedin in uterine adenosarcoma. Med Oncol 2013;30(2):501
Constantinidou A, Pollack S, Loggers E, Rodler E and Jones RL. The evolution of systemic therapy in sarcoma. Expert Rev. Anticancer Ther. 2013;2:211-223.
Ferreira BP, Rodler ET, Loggers ET, Pollack SM, Jones RL. Systemic therapy in primary angiosarcoma of the spleen. Rare Tumors 2012;4:e55.
Kurland BF, Gadi VK, Specht JM, Allison KH, Livingston RB, Rodler ET, Peterson LM, Schubert EK, Chai X, Mankoff DA, Linden HM. Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res 2012;2(1):34.